Navigation Links
Van Andel Research Institute findings provide more complete picture of kidney cancer
Date:12/29/2011

Grand Rapids, Mich. (December 29, 2011) Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.

In a study published in Cancer Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, Ph.D., researchers provide a more complete understanding of the biology of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive type of kidney cancer with no effective treatment, which lays the foundation for the development of effective treatment strategies.

Despite obvious morphological, genetic, and clinical differences, hereditary PRCC2 is thought to share similar pathway deregulation due to genetic mutation with its counterpart, clear cell renal cell carcinoma (CCRCC), a subtype that accounts for 75% of all kidney cancers and that, unlike PRCC2, responds favorably to drugs targeting vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate blood vessel formation.

The study, which included international collaboration with researchers from the National Cancer Centre Singapore, Gntique Oncologique EPFE-INSERM U753 and Facult de Mdecine Paris-Sud, Le Kremlin-Bictre and Institut de Cancrologie Gustave Roussy, Michigan State University, Northwestern Memorial Hospital, Cleveland Clinic, Singapore General Hospital, and The Wistar Institute, identified deregulation of the KEAP1-NRF2 signaling pathway as a factor that distinguishes PRCC2 from CCRCC, but links both hereditary and sporadic PRCC2.

In another study published in Cancer Research, led by Yan Ding, Ph.D., and Bin Tean Teh, Ph.D. and carried out in collaboration with the National Cancer Centre Singapore, researchers integrated gene expression profiling and RNAi screening data to identify genes involved in CCRCC development and progression.

In recent years, several molecularly targeted therapies such as sunitinib, sorafenib, and pazopanib, which target the receptor tyrosine kinases of VEGF have been approved for CCRCC. Although these therapies significantly extend overall survival, nearly all patients with advanced CCRCC eventually succumb to the disease.

Gene set enrichment analysis indicated that cell-cycle-related genes, in particular PLK1, were associated with disease aggressiveness. Further, the association of PLK1 in both disease aggression and in vitro growth prompted researchers to examine the effects of a small-molecule inhibitor in CCRCC cell lines. Their findings highlight PLK1 as a promising potential therapeutic target for CCRCC.


'/>"/>

Contact: Joe Gavan
joe.gavan@vai.org
616-234-5390
Van Andel Research Institute
Source:Eurekalert

Related medicine news :

1. Van Andel Institute study may lead to better, safer drug for diabetes
2. Van Andel Research Institute finding could lead to reduced side effects in anti-cancer antibiotics
3. Van Andel Research Institute finding is potential predictor of deadly cancer common in Asia
4. Chairman Al Brandel of Lions Clubs International Foundation to Appear in Washington DC's National Memorial Day Parade
5. AADR awards the 2010 Distinguished Mentoring Award to Irwin D. Mandel
6. Research!America Chair John Edward Porter says health research and prevention fared well in 2011
7. UT Southwestern research suggests new way to ensure effectiveness of TB treatment
8. President Obama and leading GOP presidential candidate support health research
9. Cleveland Clinic researchers honored for contributions to science
10. UK researchers present findings from Kentucky breast cancer patients with disease relapse
11. Pitt researchers propose new model to design better flu shots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... TX (PRWEB) , ... July 27, 2017 , ... ... receive a new set of teeth in a single office visit from Dr. ... and comfortable treatment solutions to his East Texas patients, including Teeth-in-a-Day® dental ...
(Date:7/27/2017)... ... July 27, 2017 , ... Somnoware, a leading ... (PSG) distributed scoring solution to its healthcare management platform. This solution provides physicians ... speed and functionality of scoring in the cloud is on par with doing ...
(Date:7/27/2017)... California (PRWEB) , ... July 27, 2017 , ... The Los Angeles leg of the ... 3rd, 2017 at 7:00pm and will be held at the Clive Davis Theater inside the ... the Camo Jacket, chronicles the story of the iconic Welsh rock musician, Mike Peters (of ...
(Date:7/27/2017)... ... 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, ... a stagiaire for the remainder of the 2017 season. One of our best development ... Tour of Utah. , “Every season we are excited to move an athlete from ...
(Date:7/26/2017)... ... July 26, 2017 , ... Capillus, LLC has announced the redesign ... The new Flexible Fitting Design offers a more comfortable, adaptable fit and is available ... the improvements to the home-use laser therapy caps intended to improve both user experience ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... LAUDERDALE, Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach ... Luncheon on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... Gendler, DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... ...
(Date:7/21/2017)... , July 21, 2017  Endo International plc (NASDAQ: ... a comprehensive review of its manufacturing network, the Company ... distribution facilities in Huntsville, Alabama . ... place over the next 12 to 18 months. The ... by declining volumes of commoditized products and these restructuring ...
(Date:7/15/2017)... 2017 Enterin Inc., a Philadelphia ... (PD), today announced the completion of a $12.7 million Series ... III, as well as the participation of existing investors. ... have the support of New Ventures III and our current ... of the potential of our platform technology to transform the ...
Breaking Medicine Technology: